Effects of calcium antagonists on the risks of coronary heart disease, cancer and bleeding. Ad Hoc Subcommittee of the Liaison Committee of the World Health Organisation and the International Society of Hypertension.
D000319:Adrenergic beta-Antagonists / Q000009:adverse effects / Q000627:therapeutic use; D002121:Calcium Channel Blockers / Q000009:adverse effects* / Q000627:therapeutic use; D015331:Cohort Studies; D003327:Coronary Disease / Q000150:complications* / Q000188:drug therapy; D006333:Heart Failure / Q000150:complications / Q000188:drug therapy; D006470:Hemorrhage / Q000139:chemically induced*; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000188:drug therapy; D009203:Myocardial Infarction / Q000209:etiology / Q000401:mortality; D009369:Neoplasms / Q000139:chemically induced* / Q000401:mortality; D016032:Randomized Controlled Trials as Topic; D018570:Risk Assessment
D000319:Adrenergic beta-Antagonists; D002121:Calcium Channel Blockers